Education
About Us
Working with TipRanks
Follow Us
Ridgetech, Inc. (RDGT)
:RDGT
Top Page
Ridgetech
(NASDAQ:RDGT)
39Underperform
Ridgetech (RDGT) vs. S&P 500 (SPY)
Market Cap
$6.61M
Dividend YieldN/A
Average Volume (3M)868.88K
Price to Earnings (P/E)―
Beta (1Y)0.48
Revenue Growth-4.87%
EPS Growth94.14%
CountryUS
Employees939
SectorHealthcare
Sector Strength76
IndustryMedical - Distribution
Share Statistics
EPS (TTM)-2.32
Shares Outstanding6,178,362
10 Day Avg. Volume193,578
30 Day Avg. Volume868,877
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.04
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Ridgetech Business Overview & Revenue Model
Company DescriptionChina Jo-Jo Drugstores (CJJD) is a retail and wholesale distributor of pharmaceutical and healthcare products in China. Operating primarily through a network of retail pharmacies, the company offers a wide range of products including prescription and over-the-counter drugs, nutritional supplements, traditional Chinese medicine, and personal care items. CJJD is committed to providing quality healthcare solutions and enhancing customer accessibility to essential medications.
How the Company Makes MoneyChina Jo-Jo Drugstores generates revenue through multiple channels. The core of its revenue model is derived from the sale of pharmaceutical products and healthcare items through its retail pharmacy outlets. The company also engages in wholesale distribution, supplying drugs to hospitals, clinics, and other pharmacies. Additionally, CJJD leverages e-commerce platforms to reach a broader customer base, providing an online sales channel for its products. Key partnerships with suppliers and manufacturers ensure a steady inventory of high-demand items, further supporting its revenue streams.
Ridgetech Financial Statement Overview
Summary
China Jo-Jo Drugstores is facing significant financial challenges across all key areas. The income statement reflects ongoing operational difficulties with consistent losses and negative margins. The balance sheet shows financial instability with high leverage and declining equity. Cash flow issues further compound these problems, with negative operational cash flows and reliance on financing activities. Overall, the company's current financial state indicates a need for strategic adjustments to improve stability and profitability.Income Statement
China Jo-Jo Drugstores has shown a declining trend in revenue with a negative revenue growth rate over the past three years. The company has been consistently reporting net losses, leading to negative net profit margins. The gross profit margin has remained relatively stable but is overshadowed by the persistent negative EBIT and EBITDA margins, indicating challenges in operational efficiency and profitability.40
Negative
Balance Sheet
The balance sheet indicates a high level of debt relative to equity, with an increasing debt-to-equity ratio over time. Stockholders' equity has been decreasing, reflecting the ongoing net losses. The equity ratio has been decreasing, signaling reduced financial stability. Overall, the company's balance sheet shows financial strain, with high leverage and declining equity.35
Negative
Cash Flow
The cash flow statement reveals negative operating cash flow, which, combined with negative free cash flow, suggests challenges in generating cash from operations. The company has also experienced a negative free cash flow growth rate, indicating deteriorating cash flow health. The financing activities have been the primary source of cash inflows, which may not be sustainable long-term.30
Negative
| Breakdown | |||||
| TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 147.13M | 154.54M | 148.81M | 164.39M | 133.13M | 117.33M | Gross Profit |
| 29.77M | 31.11M | 34.28M | 36.52M | 29.24M | 25.53M | EBIT |
| -6.01M | -3.53M | -10.57M | -2.55M | -8.61M | -6.38M | EBITDA |
| -5.06M | 1.23M | -19.96M | -579.93K | -6.08M | -3.66M | Net Income Common Stockholders |
| -5.59M | -4.23M | -21.14M | -3.20M | -8.38M | -6.46M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 5.80M | 20.15M | 18.81M | 18.55M | 22.14M | 16.33M | Total Assets |
| 67.03M | 95.06M | 90.97M | 106.38M | 106.31M | 99.52M | Total Debt |
| 25.27M | 43.22M | 42.16M | 48.67M | 46.78M | 54.45M | Net Debt |
| 19.65M | 23.07M | 23.35M | 30.22M | 24.74M | 38.27M | Total Liabilities |
| 53.32M | 80.76M | 74.30M | 83.65M | 81.91M | 80.74M | Stockholders Equity |
| 14.14M | 15.64M | 18.01M | 24.09M | 25.74M | 20.59M |
| Cash Flow | Free Cash Flow | ||||
| -14.94M | -4.08M | -3.60M | -5.69M | -666.47K | -9.19M | Operating Cash Flow |
| -13.83M | -3.16M | -3.28M | -5.39M | -62.29K | -6.91M | Investing Cash Flow |
| -1.14M | -2.04M | -316.10K | -306.14K | -2.00M | -4.84M | Financing Cash Flow |
| 15.50M | 8.00M | 2.37M | 4.84M | 3.08M | 19.01M |
Ridgetech Technical Analysis
Negative
1.07
Price Trends
1.26
Negative
1.59
Negative
1.82
Negative
Market Momentum
-0.07
Negative
44.52
Neutral
44.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RDGT, the sentiment is Negative. The current price of 1.07 is above the 20-day moving average (MA) of 1.00, below the 50-day MA of 1.26, and below the 200-day MA of 1.82, indicating a neutral trend. The MACD of -0.07 indicates Negative momentum. The RSI at 44.52 is Neutral, neither overbought nor oversold. The STOCH value of 44.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RDGT.
Ridgetech Risk Analysis
Ridgetech disclosed 58 risk factors in its most recent earnings report. Ridgetech reported the most risks in the “Legal & Regulatory” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ridgetech Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $80.26B | 17.41 | 6.07% | 4.18% | 4.02% | -43.51% | |
73 Outperform | $1.81T | 30.97 | 24.29% | ― | 10.99% | 91.61% | |
73 Outperform | $699.55B | 36.28 | 22.23% | 1.03% | 5.07% | 25.86% | |
65 Neutral | $20.37B | 18.11 | 15.89% | 2.55% | 4.96% | -32.41% | |
51 Neutral | $9.24B | ― | -60.05% | 9.36% | 5.62% | -1637.59% | |
48 Neutral | $6.36B | 1.09 | -49.92% | 2.63% | 17.17% | 0.95% | |
39 Underperform | $6.61M | ― | -27.69% | ― | -4.87% | 94.14% |
* Healthcare Sector Average
Performance Comparison
RDGT
Ridgetech
1.07
-1.93
-64.33%
AMZN
Amazon
171.00
-14.19
-7.66%
CVS
CVS Health
63.66
-7.54
-10.59%
DG
Dollar General
92.62
-61.11
-39.75%
WBA
Walgreens Boots Alliance
10.68
-7.23
-40.37%
WMT
Walmart
83.19
24.08
40.74%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.